drugset / Trial / NCT04412863
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.
Timeline
- Start
- 2020-07-03
- Primary completion
- 2024-03-25
- Completion
- 2024-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | — | Subcutaneous |
| Subject | VIR-2218 | Small interfering RNA (siRNA) | — | Subcutaneous |